Venous giant post-thrombotic chronic ulcer: successful treatment with Bosentan

2011 ◽  
Vol 26 (4) ◽  
pp. 169-172
Author(s):  
J V Solís ◽  
J L Portero ◽  
L Ribé
Keyword(s):  
Deep Vein Thrombosis ◽  
Side Effects ◽  
Medical History ◽  
Severe Hypertension ◽  
Venous Ulcer ◽  
Off Label ◽  
Vein Thrombosis ◽  
History Of ◽  
Deep Vein ◽  
Previous Medical History

Objective To report a case of a refractory post-thrombotic chronic venous ulcer managed with an off-label treatment. Method We present the case of an 82-year-old woman with a previous medical history of severe hypertension and a deep vein thrombosis three years before. A refractory giant chronic venous ulcer in her left leg was treated with Bosentan. Results The appearance of the ulcer improved in the first 45 days, worsened after an unintended stop of the treatment and was almost resolved after 90 days of treatment. Ulcer-associated pain improved very quickly and so, in only one week, opioid treatment was stopped. Bosentan treatment was well tolerated, with only mild and manageable side effects. Conclusion Treatment with Bosentan has been successful in the treatment of this case of refractory chronic venous ulcer.

scholarly journals Symptomatic Deep Vein Thrombosis Following Elective Knee Arthroscopy Over the Age of 40

2019 ◽  
Vol 25 ◽  
pp. 107602961985216 ◽  
Author(s):  
Mert Özcan ◽  
Murat Erem ◽  
Fatma Nesrin Turan
Keyword(s):  
Risk Factors ◽  
Deep Vein Thrombosis ◽  
Medical History ◽  
Symptomatic Deep Vein Thrombosis ◽  
Vein Thrombosis ◽  
Contraceptive Usage ◽  
Venous Thromboembolic Events ◽  
History Of ◽  
Deep Vein ◽  
Previous Medical History

Thromboprophylaxis following arthroscopic knee surgery (AKS) is not clear in the literature. The purpose of this study was to present the incidence of symptomatic deep vein thrombosis (DVT) following elective AKS over the age of 40. The secondary purpose was to investigate risk factors associated with venous thromboembolic events (VTEs). Surgical database and outpatient clinic follow-up charts of the patients who underwent AKS for any reason were included in the study. Odds for risk factors such as previous medical history of thrombosis, any family history for clotting disorders, diabetes mellitus (DM), oral contraceptive usage, body mass index, history of malignancy, and smoking were evaluated. The incidence of DVT following AKS significantly increased in the patients older than 40 years who had a previous medical history of VTE, DM, and smoking. A variety of guidelines exist for VTE prophylaxis; however, one should focus on risk factors related to the patient’s medical history and current medical conditions. In this study, smoking, DM, and previous history of DVT increased DVT risk significantly, and thromboprophylaxis should be kept in mind for these patients.

A murine model of deep vein thrombosis Characterization and validation in transgenic mice

2005 ◽  
Vol 94 (09) ◽  
pp. 498-503 ◽  
Author(s):  
Linda Szema ◽  
Chao-Ying Chen ◽  
Jeffrey P. Schwab ◽  
Gregory Schmeling ◽  
Brian C. Cooley
Keyword(s):  
Deep Vein Thrombosis ◽  
Murine Model ◽  
Femoral Vein ◽  
Previous History ◽  
Bed Rest ◽  
Major Surgery ◽  
Vein Thrombosis ◽  
Transgenic Lines ◽  
History Of ◽  
Deep Vein

SummaryDeep vein thrombosis (DVT) occurs with high prevalence in association with a number of risk factors, including major surgery, trauma, obesity, bed rest (>5 days), cancer, a previous history of DVT, and several predisposing prothrombotic mutations. A novel murine model of DVT was developed for applications to preclinical studies of transgenically constructed prothrombotic lines and evaluation of new antithrombotic therapies. A transient direct-current electrical injury was induced in the common femoral vein of adult C57Bl/6 mice. A non-occlusive thrombus grew, peaking in size at 30 min, and regressing by 60 min, as revealed by histomorphometric volume reconstruction of the clot. Pre-heparinization greatly reduced clot formation at 10, 30, and 60 min (p<0.01 versus non-heparinized). Homozygous FactorV Leiden mice (analogous to the clinical FactorV Leiden prothrombotic mutation) on a C57Bl/6 background had clot volumes more than twice those of wild-types at 30 min (0.121±0.018 mm3 vs. 0.052±0.008 mm3, respectively; p<0.01). Scanning electron microscopy revealed a clot surface dominated by fibrin strands, in contrast to arterial thrombi which showed a platelet-dominated structure. This new model of DVT presents a quantifiable approach for evaluating thrombosis-related murine transgenic lines and for comparatively evaluating new pharmacologic approaches for prevention of DVT.

scholarly journals Combination oral contraceptives – a practice-guided overview of everyday problems and their solutions

2020 ◽  
pp. 30-32
Author(s):  
DW Wolmarans ◽  
L Brand ◽  
SF Steyn
Keyword(s):  
Deep Vein Thrombosis ◽  
Side Effects ◽  
Adverse Effects ◽  
Oral Contraceptives ◽  
Cardiovascular Events ◽  
Treatment Withdrawal ◽  
Vein Thrombosis ◽  
Withdrawal Of Therapy ◽  
Deep Vein ◽  
Everyday Problems

Combination oral contraceptives (COCs) are some of the most commonly prescribed drugs for women between the ages of 15–451 and while they are accepted to be safe and highly effective, their use is often associated with a number of minor sideeffects. Considering the limited nature of this review, a detailed overview of the complete clinical profile of COCs falls beyond the current scope. Rather, we will focus on the most frequently reported side-effects of COCs that do not necessitate treatment withdrawal. Adverse effects that require immediate withdrawal of therapy are usually related to deep vein thrombosis (DVT) and other cardiovascular events, malignancies or hepatic pathology2 and would require a more in-depth review.

scholarly journals History of COVID-19 infection is not associated with increased d-dimer levels and risk of deep-vein thrombosis in total joint arthroplasty

2021 ◽  
Author(s):  
Anna Jungwirth-Weinberger ◽  
Ilya Bendich ◽  
Carola Hanreich ◽  
Alejandro Gonzalez Della Valle ◽  
Jason L. Blevins ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Total Joint Arthroplasty ◽  
Joint Arthroplasty ◽  
Vein Thrombosis ◽  
History Of ◽  
Deep Vein ◽  
D Dimer

Combined Venography And Arthrography In Patients With Joint Pains And A Swollen Calf

1981 ◽  
Author(s):  
J J F Belch ◽  
N McMillan ◽  
G D O Lowe ◽  
C D Forbes
Keyword(s):  
Deep Vein Thrombosis ◽  
Clinical Diagnosis ◽  
Joint Pain ◽  
Correct Diagnosis ◽  
Clinical Suspicion ◽  
Baker’S Cyst ◽  
Vein Thrombosis ◽  
Baker's Cyst ◽  
History Of ◽  
Deep Vein

Ruptured Baker’s cyst is a well recognised cause of confusion in the diagnosis of deep vein thrombosis (D.V.T.) in patients with arthralgia. Many workers have stressed the need for a high index of clinical suspicion combined with either venography or arthrography, yet in no study has simultaneous arthrography and venography been performed. Ten patients with joint pains admitted because of a swollen calf underwent bilateral ascending venography and unilateral arthrography within 24 hours of admission. Results were compared with the initial clinical diagnosis. On only one out of 10 occasions was the original clinical diagnosis correct. One patient had a D.V.T. alone, 5 patients had a Baker’s cyst and 3 patients had both D.V.T. and Baker’s cyst. One patient had no evidence of either. We conclude that any patient with a history of joint pain who develops a swollen calf should have both a venogram and an arthrogram performed in order to establish the correct diagnosis.

The Role of Stanozolol in the Treatment of the Postphlebitic Syndrome

1981 ◽  
Vol 26 (1_suppl) ◽  
pp. S81-S83 ◽  
Author(s):  
P. E. Jarrett
Keyword(s):  
Deep Vein Thrombosis ◽  
Side Effects ◽  
Fibrinolytic Activity ◽  
Double Blind ◽  
Vein Thrombosis ◽  
Postphlebitic Syndrome ◽  
Deep Vein ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

The postphlebitic syndrome is a result of previous deep vein thrombosis and presents with oedema, pain, induration, pigmentation and ulceration. Extravascular deposition of fibrin is associated with reduced fibrinolytic activity in these patients. In a double-blind crossover study there was evidence of benefit from stanozolol which enhanced fibrinolytic activity. No side effects of any consequence were noted with a dosage of 5 mg twice per day.

Sign in / Sign up

Export Citation Format

Share Document